Survey finds strong veterinary optimism on stem cell therapy: full analysis

A new AAHA-Gallant survey suggests veterinary professionals see stem cell therapy moving from niche regenerative option toward mainstream treatment for inflammatory disease. According to Gallant’s March 2 announcement, 95% of surveyed small-animal veterinary professionals said stem cell therapy will become part of the standard spectrum of care for inflammatory conditions within the next decade, reflecting strong interest in alternatives to symptom-focused management. (gallant.com)

That optimism lands in a field that has been building for years, but still carries important caveats. Regenerative medicine has expanded steadily in veterinary practice, especially around musculoskeletal disease and difficult inflammatory conditions, yet AVMA policy continues to urge caution, noting that many indications still lack definitive peer-reviewed evidence, standardized treatment regimens, and clear consensus on dosing, route, and duration. The association also emphasizes that veterinarians need to stay aligned with FDA guidance on donor eligibility, manufacturing, and product handling. (avma.org)

The new survey, titled Regenerative Medicine in Veterinary Practice: Perceptions, Experience, and Outlook, gathered responses from more than 1,000 U.S. small-animal veterinary professionals. Gallant said nearly 90% of respondents believe current therapies for inflammatory disease primarily manage symptoms rather than root causes, and about 93% said they would administer regenerative therapy if it were available as an off-the-shelf option. That framing is notable because Gallant is developing ready-to-use allogeneic stem cell products, rather than patient-specific autologous approaches that can be more logistically complex. (gallant.com)

The company’s most visible clinical program is in refractory feline chronic gingivostomatitis. A 90-day prospective multisite study published in the Journal of Feline Medicine and Surgery evaluated intravenous allogeneic uterine-derived mesenchymal stromal cells in 46 client-owned cats with refractory FCGS after partial- or full-mouth extractions. The study reported improvements in quality of life and oral lesion healing, supporting the idea that stem cell therapy could have a role in severe inflammatory disease where standard approaches fall short. Gallant also said last year that FDA’s Center for Veterinary Medicine completed the Reasonable Expectation of Effectiveness technical section for conditional approval of its FCGS product, an important regulatory milestone even though it is not full approval. (pubmed.ncbi.nlm.nih.gov)

Outside the company’s own messaging, the broader literature offers cautious encouragement rather than blanket validation. Published reports and reviews describe potential benefit for conditions such as feline chronic gingivostomatitis, eosinophilic keratitis, and other inflammatory or immune-mediated disorders, but the evidence base remains uneven across species and indications. That helps explain why enthusiasm in surveys may outpace immediate adoption in general practice: clinicians are interested, but many still want standardized products, clearer protocols, and stronger real-world data before making these therapies routine. That interpretation is an inference drawn from the survey findings alongside AVMA’s policy position and the current published literature. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this story is really about readiness. If stem cell therapies do move into the clinical mainstream, practices will need to evaluate not just efficacy claims, but sourcing, storage, administration workflows, informed consent, cost, and regulatory status. The survey points to strong professional appetite for therapies that may address inflammation more directly, especially in chronic, frustrating cases where pet parents are seeking options beyond long-term symptom control. But it also underscores the need for careful expectation-setting: interest is not the same as consensus evidence, and a commercially available off-the-shelf product would still need to prove it can deliver consistent outcomes in everyday practice. (gallant.com)

What to watch: The next markers will be additional peer-reviewed studies in target indications, further FDA-CVM progress on Gallant’s FCGS program and other cell-based products, and whether professional guidance evolves as more standardized allogeneic therapies come to market. (dvm360.com)